42967-27-1

Basic information

• Product Name: 3-[(dimethylamino)methyl]benzonitrile
• Synonyms: 3-[(dimethylamino)methyl]benzonitrile
• CAS NO: 42967-27-1
• Molecular Formula: C₁₀H₁₂N₂
• Molecular Weight: 160.22
• Mol File: 42967-27-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(dimethylamino)methyl]benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(dimethylamino)methyl]benzonitrile(42967-27-1)
• EPA Substance Registry System: 3-[(dimethylamino)methyl]benzonitrile(42967-27-1)

Safety Data

• Hazardous Substances Data: 42967-27-1(Hazardous Substances Data)

Upstream product

• 28188-41-2 m-(bromomethyl)benzonitrile 
• 24964-64-5 3-Cyanobenzaldehyde 
• 124-40-3 dimethyl amine 

Downstream Products

• 246258-97-9 1-(3-(aminomethyl)phenyl)-N,N-dimethylmethanamine 
• 1004759-80-1 N-(3'-cyanobenzyl)-N,N-dimethyl-N-[(-)-8-phenylmenthoyloxycarbonylmethyl]ammonium bromide 
• 80708-77-6 3-[(dimethylamino)methyl]-benzaldehyde 
• 24964-64-5 3-Cyanobenzaldehyde 
• 90389-96-1 3-((methylamino)methyl)benzonitrile 

Relevant articles and documents

Lewis Acid-Catalyzed Reductive Amination of Aldehydes and Ketones with N,N-Dimethylformamide as Dimethylamino Source, Reductant and Solvent

A practical zinc acetate dihydrate-catalyzed reductive amination of various carbonyl compounds with N,N-dimethylformamide (DMF) as dimethylamino (Me2N) source, reductant and solvent has been developed. This reaction shows broad substrate scope,

THIAZOLYL-DIHYDRO-CHINAZOLINE

Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Triazole derivatives

The present invention relates to triazole and imidazole derivatives of formula I and to their pharmaceutically acceptable acid addition salts. These compounds are NMDA receptor subtype blockers and are useful for the treatment of diseases related to the NMDA receptor.